

Marine Biotechnologies firm Jellagen announces the appointment of a new CEO

Cardiff, UK 14th May 2018: Jellagen, a pioneer in marine biotechnologies based in Wales, today announces the appointment of Thomas-Paul (TP) Descamps as Chief Executive Officer. He joined the Company and was appointed to the Board as an Executive Director on 17 April 2018.

Most recently, in 2013 TP moved to London to join Allergan in a European commercial role before moving in 2015 to Mayoly-Spindler, a French mid-size pharma company as VP Europe. Since 2014, TP has been acting as a Business angel and helped to raise >£4M for Jellagen during its last two last financing rounds. He is an investor and Chairman of the Board at Histide, a Swiss Biotech Start-Up.

Prior to Allergan, and after 10 years of sales and marketing roles at GSK and Eli Lilly he joined Actelion in 2004, where he was Director Commercial Operations of the French affiliate.

In 2008 he moved to Ipsen as a VP in charge of the Neurology Global portfolio management, including Franchise strategy, Product Clinical Development and Business Development.. In 2011 he successfully expanded an Ipsen US acquisition Start-Up in Europe, through 6 countries openings.

TP Holds a Master's Degree in General Management from the University Paris IX Dauphine and a Diploma of Finance and Marketing from Sciences-Po Paris.

Andrew Mearns Spragg Jellagen's Founder, Chief Scientific Officer and former CEO commented:

“When I proposed the second funding round to the Board, I was thinking to myself that on this occasion and in order to maximise the chances of Jellagen's continued successful growth, I would like to step down as CEO and to focus on what I like which is the science, innovation and product development. Jellagen's technology platform offers such a great potential so I took the opportunity to recruit a new CEO, seeking for an experienced general manager to help us scale-up our business. We then decided to appoint TP and I am delighted that we have secured a great new chief executive with a proven record within the lifescience industry. TP covers a wide array of competencies and he likes to create and lead teams to generate results. He is also very skilled at developing crosscutting strategies with a strong focus on implementation. We are looking forward to him joining our Board and driving Jellagen to the next level of success.”

Thomas-Paul Descamps commented:

“I would first like to thank Andrew for his trust and the outstanding work achieved with his team during those 4 years. I am passionate about the marine biotechnology industry and it is an honour to become the new Chief Executive of Jellagen. I am most excited by its future portfolio, which I believe could bring sustainable innovation to the cell culture and regenerative medicine areas.”

Anthony Clarke, Managing Director, Newable Private Investing [previously London Business Angels] added:

“Jellagen is a company that we have been supporting since its inception and we met Thomas-Paul during the first financing round when they also joined our Angels in MedCity programme. His input as a senior adviser and lead angel to the investor syndicate has always been very valuable. We are delighted that he is now moving into a company he already knows quite well. Andrew and TP are making a great team together”

Carmine Circelli, Technology Ventures Investment Executive, Development Bank of Wales added:

“Jellagen is a great example of an exciting Welsh business that’s pushing technological boundaries. In start-ups, transition phases are often delicate and we are very pleased to see Jellagen success to attract a Senior Executive leader at the time of commercialisation. Supporting businesses like Jellagen is at the core of our mission, and we look forward to hearing of their future success, lead by TP and Andrew.”

--- Ends ---

About Jellagen

Jellagen Pty Ltd founded in 2013, is a marine biotechnology Company based in Cardiff, whose strategic mission is to exploit sustainable marine species and natural resources, to develop technical and scientific high value products, meeting state of the art specifications. The first products developed by Jellagen are based on Next Generation Collagen extracted from Jellyfish. The first range of products developed through this new technology, are cell culture reagents used to grow stem cells in 2D and 3D by the Biotech and Pharma Industry R&D teams. The second range of products will be medical devices and biomaterials in the areas of wound and regenerative medicine, also engineered around jellyfish collagen. <http://www.jellagen.co.uk/>

About Newable Private Investing Limited

Newable Private Investing (formerly London Business Angels) is a leading provider of early stage equity finance to potentially high growth companies through its sector focussed private investor groups, proprietary funds and co-investment partners. NPI is part of the wider Newable group <https://www.newable.co.uk/private-investing/>

About Development Bank of Wales

The Development Bank of Wales was set up by the Welsh Government to support the economy of Wales by making it easier for businesses to get the finance needed to start up, strengthen and grow. The purpose of the Development Bank is to unlock potential in the economy of Wales by increasing the provision of sustainable, effective finance in the market.

Launched in October 2017 it will become a cornerstone organisation for delivery of public sector financial products, supporting micro to medium businesses in Wales and increasing the supply of finance. It will promote economic development through an adaptable delivery model that is responsive to market needs whilst providing continued value for money for public funds. It will deliver key Welsh Government policy objectives measured through performance targets and providing investment management and support services across the whole of Welsh Government.

Formerly known as Finance Wales, it has supported Welsh businesses with investment funds since 2001. It has directly invested £0.5 billion into Welsh businesses and attracted £0.7 billion of private sector investment. Together this has boosted the Welsh economy by over £1.2 billion. (figures as at 31st December 2017) . Now as the Development Bank of Wales it has over £1 billion of funds under management which includes administration of the Help to Buy – Wales shared equity scheme.